News | July 23, 2021
Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Subscribe To Our Newsletter & Stay Updated
